Celltrion said on the 6th that it held an opening ceremony for a biopharmaceutical manufacturing facility in Branchburg, New Jersey. Celltrion purchased the facility from Eli Lilly and Company. The company said it has secured a production base in the United States and resolved tariff risk.
Todd Wingja was appointed as the new CEO of Celltrion Branchburg LLC. The company signed a contract with Eli Lilly and Company for contract manufacturing of biologic drug substances and succeeded employment. Celltrion plans to accelerate its business by linking local U.S. manufacturing with a direct sales system.
Seo Jung-Jin, chair of the Celltrion Group, said, "We will expand the Branchburg production facility into a comprehensive contract development and manufacturing base that includes a research center." Attendees at the event included U.S. New Jersey Sen. Andy Kim, U.S. New Jersey Rep. Thomas Kean Jr., and Branchburg Township President Thomas Young.